Literature DB >> 17904302

Phase II study of preoperative helical tomotherapy for rectal cancer.

Mark De Ridder1, Koen Tournel, Yves Van Nieuwenhove, Benedikt Engels, Anne Hoorens, Hendrik Everaert, Bart Op de Beeck, Vincent Vinh-Hung, Jacques De Grève, Georges Delvaux, Dirk Verellen, Guy A Storme.   

Abstract

PURPOSE: To explore the efficacy and toxicity profile of helical tomotherapy in the preoperative treatment of patients with rectal cancer. PATIENTS AND METHODS: Twenty-four patients with T3/T4 rectal cancer were included in this nonrandomized noncontrolled study. A dose of 46 Gy in daily fractions of 2 Gy was delivered to the presacral space and perineum if an abdominoperineal resection was deemed necessary. This dose was increased by a simultaneous integrated boost to 55.2 Gy when the circumferential resection margin was less than 2 mm on magnetic resonance imaging. Acute toxicity was evaluated weekly. Metabolic response was determined in the fifth week after the end of radiotherapy by means of fluorodeoxyglucose-positron emission tomography scan. A metabolic response was defined as a decrease in maximal standardized uptake value of more than 36%.
RESULTS: The mean volume of small bowel receiving more than 15 Gy and mean bladder dose were 227 ml and 20.8 Gy in the no-boost group and 141 ml and 21.5 Gy in the boost group. Only 1 patient developed Grade 3 enteritis. No other Grade 3 or 4 toxicities were observed. Two patients developed an anastomotic leak within 30 days after surgery. The metabolic response rate was 45% in the no-boost group compared with 77% in the boost group. All except 1 patient underwent an R0 resection.
CONCLUSIONS: Helical tomotherapy may decrease gastrointestinal toxicity in the preoperative radiotherapy of patients with rectal cancer. A simultaneous integrated radiation boost seems to result in a high metabolic response rate without excessive toxicity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17904302     DOI: 10.1016/j.ijrobp.2007.07.2332

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  14 in total

Review 1.  Advances in radiotherapy and targeted therapies for rectal cancer.

Authors:  Alexandra Sermeus; Wim Leonard; Benedikt Engels; Mark De Ridder
Journal:  World J Gastroenterol       Date:  2014-01-07       Impact factor: 5.742

Review 2.  Image-guided radiation therapy (IGRT): practical recommendations of Italian Association of Radiation Oncology (AIRO).

Authors:  Paola Franzone; Alba Fiorentino; Salvina Barra; Domenico Cante; Laura Masini; Elena Cazzulo; Liana Todisco; Pietro Gabriele; Elisabetta Garibaldi; Anna Merlotti; Maria Grazia Ruo Redda; Filippo Alongi; Renzo Corvò
Journal:  Radiol Med       Date:  2016-09-06       Impact factor: 3.469

3.  Three-dimensional patient setup errors at different treatment sites measured by the Tomotherapy megavoltage CT.

Authors:  S K Hui; E Lusczek; T DeFor; K Dusenbery; S Levitt
Journal:  Strahlenther Onkol       Date:  2012-03-09       Impact factor: 3.621

4.  The first thermic treatment predicts following chemoradiation response with concurrent thermal therapy for the treatment of rectal cancer.

Authors:  Hisanori Shoji; Masahiko Motegi; Kiyotaka Osawa; Takayuki Asao; Hiroyuki Kuwano; Takeo Takahashi; Kyoji Ogoshi
Journal:  Oncol Lett       Date:  2018-05-04       Impact factor: 2.967

5.  Short course radiotherapy with simultaneous integrated boost for stage I-II breast cancer, early toxicities of a randomized clinical trial.

Authors:  Hilde Van Parijs; Geertje Miedema; Vincent Vinh-Hung; Sylvia Verbanck; Nele Adriaenssens; Dirk Kerkhove; Truus Reynders; Daniel Schuermans; Katrien Leysen; Shane Hanon; Guy Van Camp; Walter Vincken; Guy Storme; Dirk Verellen; Mark De Ridder
Journal:  Radiat Oncol       Date:  2012-06-01       Impact factor: 3.481

6.  A novel strategy of radiofrequency hyperthermia (neothermia) in combination with preoperative chemoradiotherapy for the treatment of advanced rectal cancer: a pilot study.

Authors:  Hisanori Shoji; Masahiko Motegi; Kiyotaka Osawa; Noriyuki Okonogi; Atsushi Okazaki; Yoshitaka Andou; Takayuki Asao; Hiroyuki Kuwano; Takeo Takahashi; Kyoji Ogoshi
Journal:  Cancer Med       Date:  2015-02-09       Impact factor: 4.452

7.  Implementation of HybridArc treatment technique in preoperative radiotherapy of rectal cancer: dose patterns in target lesions and organs at risk as compared to helical Tomotherapy and RapidArc.

Authors:  Thierry Gevaert; Benedikt Engels; Cristina Garibaldi; Dirk Verellen; Peter Deconinck; Michael Duchateau; Truus Reynders; Koen Tournel; Mark De Ridder
Journal:  Radiat Oncol       Date:  2012-07-31       Impact factor: 3.481

8.  Future directions in combined modality therapy for rectal cancer: reevaluating the role of total mesorectal excision after chemoradiotherapy.

Authors:  Abhishek A Solanki; Daniel T Chang; Stanley L Liauw
Journal:  Onco Targets Ther       Date:  2013-08-14       Impact factor: 4.147

9.  Helical tomotherapy combined with capecitabine in the preoperative treatment of locally advanced rectal cancer.

Authors:  Ming-Yii Huang; Chin-Fan Chen; Chun-Ming Huang; Hsiang-Lin Tsai; Yung-Sung Yeh; Cheng-Jen Ma; Chan-Han Wu; Chien-Yu Lu; Chee-Yin Chai; Chih-Jen Huang; Jaw-Yuan Wang
Journal:  Biomed Res Int       Date:  2014-05-06       Impact factor: 3.411

10.  Breast conserving treatment for breast cancer: dosimetric comparison of sequential versus simultaneous integrated photon boost.

Authors:  Hilde Van Parijs; Truus Reynders; Karina Heuninckx; Dirk Verellen; Guy Storme; Mark De Ridder
Journal:  Biomed Res Int       Date:  2014-08-04       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.